Journal: Effects of AFQ056 on language learning in fragile X syndrome
Product Description:
FXLEARN, the first-ever large multi-site trial of effects of disease-targeted pharmacotherapy on learning, was designed to explore a new paradigm for measuring effects of mechanism-targeted treatment in fragile X syndrome (FXS).
Keyword(s):
Language, Fragile X, AFQ056
Product/Publication Type(s):
Peer-reviewed publications in scholarly journals Published/In Press
Target Audience:
Professionals, Students
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A